From Data to Decision: Integrating Bioinformatics into Glioma Patient Stratification and Immunotherapy Selection

TL;DR

This review discusses how bioinformatics tools can help classify glioma patients and guide immunotherapy choices by analyzing genetic and molecular data.

Contribution

The paper provides a comparative analysis of bioinformatic tools for glioma patient stratification and highlights their potential in immunotherapy selection.

Findings

Bioinformatics tools aid in identifying biomarker genes and potential targets for targeted therapy in gliomas.

Integrative data analysis can predict immunotherapy efficacy by assessing tumor mutational burden and immune microenvironment.

Current tools show promise but remain largely in preclinical research, not yet transforming clinical practice.

Abstract

Gliomas are notoriously difficult to treat owing to their pronounced heterogeneity and highly variable treatment responses. This reality drives the development of precise diagnostic and prognostic methods. This review explores the modern arsenal of bioinformatic tools aimed at refining diagnosis and stratifying glioma patients by different malignancy grades and types. We perform a comparative analysis of software solutions for processing whole-exome sequencing data, analyzing DNA methylation profiles, and interpreting transcriptomic data, highlighting their key advantages and limited applicability in routine clinical practice. Special emphasis is placed on the contribution of bioinformatics to fundamental oncology, as these tools aid in the discovery of new biomarker genes and potential targets for targeted therapy. The ninth section discusses the role of computational models in predicting immunotherapy efficacy. It demonstrates how integrative data analysis—including tumor mutational burden assessment, characterization of the tumor immune microenvironment, and neoantigen identification—can help identify patients who are most likely to respond to immune checkpoint inhibitors and other immunotherapeutic approaches. The obtained data provide compelling justification for including immunotherapy in standard glioma treatment protocols, provided that candidates are accurately selected based on comprehensive bioinformatic analysis. The tools discussed pave the way for transitioning from an empirical to a personalized approach in glioma patient management. However, we also note that this field remains largely in the preclinical research stage and has not yet revolutionized clinical practice. This review is intended for biological scientists and clinicians who find traditional bioinformatic tools difficult to use.

Figures